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Abstract
Background: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor fibroblast growth factor-
inducible 14 (Fn14) are upregulated after myocardial infarction (MI) in both humans and mice. They modulate inflammation
and the extracellular matrix, and could therefore be important for healing and remodeling after MI. However, the function of
TWEAK after MI remains poorly defined.
Methods and results: Following ligation of the left coronary artery, mice were injected twice per week with a recombinant
human serum albumin conjugated variant of TWEAK (HSA-Flag-TWEAK), mimicking the activity of soluble TWEAK.
Treatment with HSA-Flag-TWEAK resulted in significantly increased mortality in comparison to the placebo group due to
myocardial rupture. Infarct size, extracellular matrix remodeling, and apoptosis rates were not different after MI. However,
HSA-Flag-TWEAK treatment increased infiltration of proinflammatory cells into the myocardium. Accordingly, depletion of
neutrophils prevented cardiac ruptures without modulating all-cause mortality.
Conclusion: Treatment of mice with HSA-Flag-TWEAK induces myocardial healing defects after experimental MI. This is
mediated by an exaggerated neutrophil infiltration into the myocardium.
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Introduction
Heart failure (HF) is a major cause of mortality in industrialized
countries affecting approximately 1–2% of the adult population
[1]. The most common reason of HF is an incompletely reperfused
myocardial infarction (MI) with subsequent maladaptive left
ventricular (LV) remodeling. The immune system plays a major
role in the reparative/remodeling response following ischemic
injury. It is activated early and subsequently clears cellular debris.
In the sub-acute granulation or healing phase, inflammatory cells
are necessary for the development of a solid scar [2]. Therefore, in
the first phases after MI inflammation is a prerequisite for proper
healing. However, in the final remodeling phase, it is important
that inflammation is downregulated. A chronic elevation of
intramyocardial proinflammatory cytokines, including interleukin
(IL)-6 [3] and tumor necrosis factor (TNF) a [4], are associated
with adverse cardiac remodeling.
TWEAK is a member of the TNF ligand family and is up-
regulated after MI [5]. It is initially expressed as a type II
transmembrane protein but typically processed with high efficacy
by furin-like proteases to a soluble form [6]. TWEAK functions
mainly by binding to its receptor fibroblast growth factor-inducible
molecule 14 (Fn14), which has the potential to activate both the
classical and alternative nuclear factor-kB (NFkB) [7] as well as
various MAPK pathways [8]. It is involved in cell proliferation, -
differentiation, apoptosis, angiogenesis, and inflammation [9].
TWEAK exists in two forms: 1) the initially expressed membrane
bound form that efficiently triggers all known Fn14-related
signaling events including the classical NFkB pathway, and 2)
the processed soluble form that activates the alternative NFkB
pathway and enhances TNF-induced cell death. The latter form
only shows limited pro-inflammatory activities via the classical
NFkB pathway and MAP kinases [7,10].
The function of TWEAK in cardiovascular diseases is
controversial. On the one hand, overexpression of full length,
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thus membrane-bound TWEAK causes dilated cardiomyopathy
and cardiac dysfunction in mice. This effect is mediated
exclusively by Fn14 receptor and is associated with cardiomyocyte
elongation and cardiac fibrosis but not with cardiomyocyte
apoptosis [11]. On the other hand, exogenous application of the
soluble TWEAK induced hypoxic and ischemic tolerance in vitro
and in vivo in mouse models of cerebral ischemia and decreased the
volume of ischemic lesions after transient middle cerebral artery
occlusion in an Fn14-dependant manner. This effect was mediated
by TNFa and ERK 1/2 activation via phosphorylation of BAD
[12]. The divergent findings after ischemia might be due to
different effects of the TWEAK forms. Cardiac overexpression of a
full length TWEAK resembles the membrane bound form and
therefore triggers classical NFkB-signaling, a pathway known to be
maladaptive after cardiac ischemia [13,14].
Due to its immunomodulatory effects, its role in healing, and
ischemic protection after stroke we hypothesized that in contrast to
membrane bound TWEAK soluble TWEAK could be a
cardioprotective target after MI. Thus, we applied a genetically
engineered construct after MI that contains soluble form of
TWEAK attached to serum albumin domain (HSA-Flag-
TWEAK). This chimeric protein possesses an improved serum
half-life compared to conventional soluble TWEAK [7].
Materials and Methods
Ethics Statement
This study conforms to the ‘‘Guide for the Care and Use of
Laboratory Animals’’ published by the US National Institutes of
Health. All experiments were performed according to the German
regulations for animal experimentation. The study was approved
by the Regierung von Unterfranken as the responsible authority
(Permit Number 55.2-2531.01-01/10). All surgery was performed
under isoflurane or tribromoethanol anesthesia, and all efforts
were made to minimize suffering.
Animals
Eight- to ten-week-old male C57BL/6J mice were obtained
from Harlan Laboratories (Eystrup, Germany) and were random-
Figure 1. MI induces the expression of TWEAK and Fn14 in the mouse heart. (A) TWEAK and (B) Fn14 mRNA expression were significantly
increased 3 days after experimental MI. Fn14 mRNA expression was significantly increased after 8 weeks of MI. (C) Immunohistological staining after
3 day of MI revealed high expression of Fn14 protein in the border zone of the myocardium co-localizing with periostin expression. (D) Periostin
positive fibroblasts are the main source of Fn14 expression in the infarcted heart and aSAA positive cardiomyocytes show no expression of Fn14. (E)
Isolated cardiac mouse fibroblasts express Fn14 whereas (F) isolated cardiomyocytes show no Fn14 expression.
doi:10.1371/journal.pone.0078938.g001
Figure 2. HSA-Flag-TWEAK increases mortality and cardiac
ruptures after MI. (A) Percent survival was significantly deceased in
HSA-Flag-TWEAK treated mice after MI compared to placebo-treated
mice. (B) Most HSA-Flag-TWEAK treated mice died because of left
ventricular ruptures.
doi:10.1371/journal.pone.0078938.g002
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Table 1. HSA-Flag-TWEAK does not affect echocardiographic measurements after MI.
Parameter PBS, sham HSA-Flag-TWEAK, sham PBS, MI HSA-Flag-TWEAK, MI
Day 1
n 3 3 9 17
Heart rate (bpm) 473619 440615 462629 495616
Papillary
ESA (mm2) 760.4 5.760.3 12.260.7 11.760.5
EDA (mm2) 1060.8 7.660.4 14.560.5 14.260.6
2D FS (%) 29.663.0 2560 16.162.5 17.461.5
Apical
ESA (mm2) 7.660.4 761.0 13.560.8 11.960.7
EDA (mm2) 11.260.7 9.960.5 15.760.9 14.160.7
2D FS (%) 32.364.9 29.866.4 14.161.7 15.761.8
Day 3
N 3 3 7 15
Heart rate (bpm) 47363 480647 563623 561611
Papillary
ESA (mm2) 861.15 6.460.8 12.961.3 12.760.8
EDA (mm2) 10.361.45 8.761.2 15.461.3 1560.8
2D FS (%) 22.761.46 25.363.1 17.362.0 15.861.2
Apical
ESA (mm2) 7.660.29 8.261.4 12.861.4 12.760.8
EDA (mm2) 10.860.62 10.961.7 15.461.56 1560.8
2D FS (%) 29.762.18 2562.2 17.161.6 16.561.8
Animals underwent echocardiography on day 1, day 3, day 21 (data not shown) and day 56 (data not shown) after MI. All measurements were recorded at the
midpapillary level which shows changes in the dimensions of the surviving non-infarcted myocardium, as well as on the apical level depicting changes in scar formation.
Data are means 6 sem; n indicates number of animals studied. EDA, end-diastolic area; ESA, end-systolic area; FS, fractional shortening; 2D, 2-dimensional.
doi:10.1371/journal.pone.0078938.t001
Figure 3. HSA-Flag-TWEAK fails to modulate extracellular matrix remodeling after MI. mRNA-expression of (A) collagen1a1, collagen1a2,
(B) MMP-2, MMP-3, MMP-8, and MMP-9 were unaffected in the scar region of HSA-Flag-TWEAK challenged mice as were the (C) zymographic activities
of MMP-2 and MMP-9 (measured as gel band intensity) and (D) TIMP-2, TIMP-3, and VEGF mRNA expression.
doi:10.1371/journal.pone.0078938.g003
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ized into two treatment groups: HSA-Flag-TWEAK and placebo.
The recombinant protein was produced as described previously
[15].
Animals had free access to standard chow and drinking water
and were kept under specific pathogen-free conditions.
Isolation of Primary Cardiac Mouse Fibroblast and
Myocytes
Left ventricular tissue from healthy mice was minced into small
pieces, digested as described and transferred into tissue culture
flasks in Dulbecco’s modified eagle media (DMEM, Lonza,
Cologne, Germany) supplemented with 10% fetal bovine serum
[16]. For the isolation of primary adult mouse cardiac myocytes
the heart was first perfused with calcium-free buffer, digested as
described and perfused with calcium buffer [17]. Cardiomyocytes
were cultured in Modified Eagle’s Medium (MEM), supplemented
with 10% bovine serum albumin.
Experimental MI
MI was induced in mice as described previously [18]. In brief,
mice were anesthetized with isoflurane (Abbott GmbH & Co. KG,
Wiesbaden, Germany) intubated, and put on a mechanical small-
animal ventilator (MiniVent, Hugo Sachs Elektronik, March-
Hugstetten, Germany). After left-sided thoracotomy, ligation of
the left coronary artery with a PE-10 tube on top of the vessel was
performed with a 6-0 silk suture, 2–3 mm from the tip of the left
auricle. The chest wall was closed with a continuous 6-0 prolene
suture and the skin with a 4-0 polyester suture. In sham-operated
mice, a thoracotomy was performed to expose the heart, but the
coronary artery was not ligated. Mice were injected intraperito-
neally (i.p.) with HSA-Flag-TWEAK (32 mg/mouse) or placebo
control (PBS, 200 ml/mouse) right after inducing myocardial
infarction. The optimal HSA-Flag-TWEAK dose was previously
determined by us [15,19]. Treatment with TWEAK or placebo
control was repeated six times for 3 weeks. Animals were sacrificed
8 weeks after MI.
Detection of Cardiac Rupture
Autopsy was performed on all animals either found dead or
sacrificed at the end of the study period. Cardiac rupture was
confirmed by the presence of clotted blood in the chest and
perforation of the infarcted wall, as described previously [20].
Echocardiography
Ultrasound analyses (Toshiba Aplio system, Neuss, Germany)
were performed by a single researcher experienced in rodent
echocardiography at day 1, 21 and 56 after MI as described before
[18]. For the procedure, mice were put under light general
anesthesia with isoflurane to allow for spontaneous respiration.
From two-dimensional short axis imaging, endocardial borders
were traced at end-systole and end-diastole utilizing a prototype
off-line analysis system (NICE, Toshiba Medical Systems,
Zoetermeer, Netherlands). Measurements were performed at the
mid-papillary muscle level. The end-systolic (smallest) and end-
diastolic (largest) cavity areas were determined. Using the end-
systolic and -diastolic areas, fractional area changes were
calculated [(end-diastolic area - end-systolic area)/end-diastolic
area]. From two-dimensionally targeted M-mode tracings, end-
diastolic diameter and end-systolic diameter were measured.
Fractional shortening was calculated.
Figure 4. HSA-Flag-TWEAK does not induce cardiomyocyte apoptosis. The percentage of apoptotic cells 3 days after MI as assessed by
immunofluorescence microscopy for (A) TUNEL-positive cells and (B) cleaved PARP was similar between HSA-Flag-TWEAK and PBS treated mice.
doi:10.1371/journal.pone.0078938.g004
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Histology and Immunohistology
Sections of mouse myocardium were embedded in Tissue Tek
(Sakura, Alphen aan den Rijn, Netherlands) and 7-mm cryosec-
tions were prepared. Cells were labelled with mouse-anti-mouse
Fn14 (clone ITEM-4; eBioscience, Frankfurt, Germany), rat-anti-
mouse neutrophils (clone 7/4; Linaris, Germany), or rabbi-anti-
mouse periostin (BioVendor, Heidelberg, Germany). For the
labelling of cleaved PARP, formalin fixed sections of mouse
myocardium were prepared in the standard manner. Sections
were treated with an anti-peroxidase complex and histoprime
enhancer (Linaris, Dossenheim, Germany) before the application
of the primary rabbit-anti-mouse cleaved PARP antibody (abcam,
Cambridge, United Kingdom). The secondary antibodies were
Alexa Fluor 647 goat anti-rabbit IgG (invitrogen), Alexa Fluor 647
goat anti-mouse IgG (invitrogen) and Alexa Fluor 350 goat anti-rat
IgG (invitrogen). The slides were embedded in mounting medium
(Vector Labs, Peterborough, United Kingdom). Images were
obtained with an AxioCamMR3 camera, mounted on an Axio
Imager.Z1 microscope (Carl Zeiss, Jena, Germany) equipped with
AxioVision software (version 4.8.3.0). 7-mm sections were stained
according to a standard hematoxylin-and-eosin staining protocol
and embedded in Entellan (Merck, Darmstadt, Germany) for light
microscopy (Axioskop 2 plus, Carl Zeiss, Jena, Germany; software:
SPOT Basic, version 5.0). For the determination of collagen
content, collagen was stained with picrosirius red (picrosirius red
F3BA, Polysciences Inc., Warren, Pennsylvania, USA) on 5-mm
sections, as described recently [18]. The slides were washed with
phosphate buffered saline (PBS) and embedded in Entellan.
Real-Time Reverse Transcriptase–polymerase Chain
Reaction
Total RNA was isolated using the RNeasy Mini kit (Qiagen,
Hilden, Germany) and cDNA reverse transcription was performed
with iScript cDNA synthesis kit (BioRad, München, Germany)
according to manufacturer’s instructions. Real-time polymerase
chain reaction (PCR) procedures were performed with commer-
cially available TaqMan probes (Applied Biosystems, Bedford,
USA) for GAPDH, TWEAK, Fn14, MMP2, MMP3, MMP8,
MMP9, collagen1a1, collagen1a2, TIMP2, TIMP3, and VEGF as
reported previously [18]. Target gene ratios were normalized to
GAPDH.
Figure 5. HSA-Flag-TWEAK treatment modulates the expression of cytokines and chemokines via NFkB and JAK/STAT-signalling.
The protein-protein interaction network maps cytokine and chemokine data from the protein microarrays onto the human interactome. Circles
indicate proteins; kinases are depicted in triangular shape, each specified by gene names. They are connected either by gray lines indicating protein-
protein interactions or red arrows denoting phosphorylation reactions. The functional entities are highlighted (interleukins, chemokines, JAK/STAT
pathway). Green-colored nodes show up-regulation in the TWEAK stimulation (orange) condition.
doi:10.1371/journal.pone.0078938.g005
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Infarct Size Measurement after Myocardial Infarction
Infarct size measurements after 6 hours of MI were performed
as recently described [21]. In short, animals were put under
general anesthesia with isoflurane and intubated using a ventilator.
The chest was opened and 5% Evans blue (Sigma-Aldrich,
Munich, Germany) in PBS was injected into the apex of the heart.
After the animals were sacrificed by intracardiac injection of
saturated KCl solution in PBS, the heart was removed, washed
with 0.9% NaCl and frozen in Tissue Tek (Sakura, Alphen aan
den Rijn, Netherlands) at 220uC for 30 minutes. The frozen heart
was cut into five parallel transverse slices, which were stained with
2% 2,3,5-Triphenyl-tetrazolium chloride (TTC) (Sigma-Aldrich,
Munich, Germany) for 10 min at 37uC. After TTC staining,
viable myocardium stains red and the infarcted areas appear pale.
Slices were weighed, imaged and the area of infarction for each
section was determined by computerized planimetry using an
image analysis software program (VGA Planimetrie 2010 for
Canon EOS5D and Planimetrie Report for Microsoft Excel 2010).
Cytokine Arrays
Cytokine levels within the myocardium of placebo or HSA-
Flag-TWEAK treated animals were analyzed 3 days after
Table 2. HSA-Flag-TWEAK modulates the production of cytokines in the infarcted heart after MI.
PBS HSA-Flag-TWEAK
abbreviation/gene name expression [pg/ml] SEM expression [pg/ml] SEM p
BLC/B-lymphocyte chemoattractant 116,18 5,54 110,40 4,81 N.S.
CD40 10,18 0,64 12,82 1,35 N.S.
CXCL16/Chemokine (C-X-C motif) ligand 16 0,50 0,30 0,43 0,43 N.S.
Eotaxin 10,52 0,31 11,63 0,36 N.S.
Eotaxin-2 15,26 0,43 16,09 0,52 N.S.
E-Selectin 40,71 2,92 45,90 5,04 N.S.
GITR/glucocorticoid induced tumor
necrosis factor receptor family related gene
64,45 10,41 99,69 4,95 p,0.05
GM-CSF/Granulocyte macrophage
colony-stimulating factor
2,54 1,19 2,70 1,61 N.S.
ICAM-1 420,03 107,50 365,54 186,63 N.S.
IFN-c u.d. 7,47 5,75 p,0.05
IL-12/Interleukin-12 u.d. 44,51 3,23 p,0.05
IL-12p40/70 90,43 40,35 73,85 45,21 N.S.
IL-2/Interleukin-2 6,08 1,65 6,22 1,91 N.S.
IL-3/Interleukin-3 0,27 0,26 1,04 0,77 N.S.
IL-5/Interleukin-5 4,13 2,66 18,75 5,05 p,0.05
IL-9/Interleukin-9 241,45 16,66 291,12 16,77 N.S.
KC/keratinocyte-derived chemokine 1,29 0,72 2,89 0,58 N.S.
MCP-1/monocyte chemotactic protein-1 u.d. 21,54 7,27 p,0.05
MCP-5/monocyte chemoattractant protein-5 u.d. 7,36 3,65 p,0.05
MDC/macrophage-derived chemokine 19,18 1,99 22,49 1,54 N.S.
MIP-1c/macrophage inflammatory protein c 412,09 117,66 747,38 107,42 N.S.
MIP-2/macrophage inflammatory protein-2 1,41 0,88 7,83 3,22 N.S.
MIP-3a/macrophage inflammatory protein-3a 7,49 0,36 7,67 0,39 N.S.
OPG/Osteoprotegerin 39,80 2,60 49,27 3,46 N.S.
Osteopontin 17780,54 5216,12 22152,46 4037,31 N.S.
PF4/platelet factor 4 785,01 69,99 1362,01 337,63 N.S.
P-Selectin 363,30 40,92 551,42 105,86 N.S.
RANTES/regulated on activation, normal
T cell expressed and secreted
u.d. 4,63 3,34 p,0.05
Resistin 34,46 5,18 43,76 16,07 N.S.
sTNFRII 14,77 0,94 17,12 1,38 N.S.
VCAM-1/vascular cell adhesion molecule 1 168,49 23,01 257,27 43,26 N.S.
VEGF-D/vascular endothelial growth factor D 91,54 12,95 84,96 5,79 N.S.
u.d. = under detection limit.
IFN-c: ,11 pg/ml; IL-12: ,5 pg/ml; MCP-1: ,5 pg/ml; MCP-5: ,1 pg/ml; RANTES: ,3 pg/ml.
A cytokine array for the detection of the protein expression of different cytokines was performed 3 days after MI. HSA-Flag-TWEAK treated mice showed statistically
significant up-regulation of interleukin 12 (IL-12), interleukin 5 (IL-5), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-2 (MIP-2) and
regulated on activation, normal T cell expressed and secreted (RANTES) (u.d. = under limit of detection).
doi:10.1371/journal.pone.0078938.t002
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myocardial infarction using Quantibody mouse cytokine array
Q2000 (RayBiotech, Norcross GA, USA) according to the
manufacturer’s protocol. Standard curves of the cytokines were
generated using Origin 8.5.1 (OriginLab, Northampton, USA)
following background subtraction.
Bioinformatic Gene Expression Analysis based on
Cytokine Array Results
Gene expression data were normalized and significantly higher
expressed genes (ANOVA t-test) were mapped on the interactome.
The human interactome network including kinases and phos-
phorylation substrate information was established for the cardio-
myocyte as described previously for the platelet [22]. Briefly,
different proteome and transcriptome databases were collated
regarding protein nodes with expression evidence in the cardio-
myocyte. Information on human protein-protein interactions
(PPIs) was obtained from the Human Protein Reference Database
(HPRD; version 9.0, April 2010) [23] and the Entrez Gene
National Center for Biotechnology Information (NCBI) server [24]
and visualized with Cytoscape (version 2.8.3). It was combined
with data on protein phosphorylation from HPRD (version 9.0)
and PhosphoSite as well as kinase predictions for phosphopro-
teome data using the NetworKIN algorithm [25,26]. Furthermore,
interaction predictions were generated from a number of protein-
protein interaction databases such as HPRD. Gene and protein
names were taken according to RefSeq records. A comprehensive
list of human kinases was extracted from Manning et al. (2002)
and used for reference and validation of the HPRD phosphory-
lation data [27].
Gelatine Zymography
Zymography, based on a SDS-PAGE method, was performed
to determine colagenolytic activities of MMP-2 and MMP-9 in
homogenized heart tissue of placebo- and HSA-Flag-TWEAK-
treated WT mice. For protein isolation, myocardium tissue of the
infarcted area was homogenized with Ripa buffer and PMSF (Cell
Signaling, Frankfurt, Germany). The samples were separated on a
10% polyacrylamide gel containing 2.5 mg/ml gelatine at a
constant voltage of 120 V for 2 h at 4uC. After electrophoresis, the
proteins were renaturated by incubation of the gels in 2.5% Triton
X-100 (Sigma-Aldrich) for 90 min at room temperature. The gels
were then incubated in activation buffer (50 mM Tris-HCl,
pH 7.5, 5 mM CaCl2, 0.2 M NaCl, and 0.02% Brij-35) for 12 h
at 37uC. Finally, the gels were stained for 1 h at RT using 0.5%
coomassie blue staining solution and then destained in 40% v/v
methanol, 10% v/v acetic acid to reveal bands of clearing which
indicate proteolytic activity. The band intensity was quantified
using ImageJ (version 1.44p).
Terminal Deoxynucleotidyl Transferase-mediated dUTP
Nick-end Labeling (TUNEL) Assay
Nuclear DNA fragmentation (In Situ Cell Death Detection Kit,
Fluorescein, Roche Diagnostics, Mannheim, Germany) was used
as a marker for apoptosis. Sections of mouse myocardium were
fixed in 4% paraformaldehyde overnight, embedded in paraffin,
sectioned, and stained according to the manufacturer’s instruc-
tions. TUNEL-positive cells were counted in the border zone area
- defined as the zone bordering the infarct where viable
myocardium was prevalent and reparative fibrosis was only
marginal - and in the remote unaffected myocardium (septum
region).
Figure 6. HSA-Flag-TWEAK increases immune cell infiltration into the infarcted heart. (A) Exogenous administration of HSA-Flag-TWEAK
amplified the infiltration of leukocytes into the infarcted myocardium 3 days after MI as determined by FACS analysis. (B) Neutrophils highly
infiltrated the border zone of HSA-Flag-TWEAK treated mice.
doi:10.1371/journal.pone.0078938.g006
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Fluorescence-Activated Cell Sorting (FACS)
For the quantification of infiltrating immune cells into mouse
hearts, the monoclonal antibody anti-mouse CD45 eFluor450
(eBioscience, Frankfurt, Germany) was used. For the exclusion of
dead cells 7-Amino-Actinomycin D (7-AAD) was used (BD
Pharmingen).
Hearts were harvested, the ischemic parts were isolated, and the
tissue was digested in a suspension of collagenase (100 mg/ml;
Sigma-Aldrich, Schnelldorf, Germany) and protease XIV (prote-
ase from Streptomcyces griseus, 50 mg/ml; Sigma-Aldrich) in PBS
with calcium and magnesium for 30 minutes at 37uC. A single cell
suspension was prepared by filtering the tissue through a 40-mm
cell strainer (BD Falcon, Heidelberg, Germany). 106 cells per
staining were washed with 100 ml FACS buffer (0.1% BSA, 0.02%
NaN3 in PBS) once. To block unspecific Fcc RIII/II receptors,
cells were incubated with saturating amounts of cell culture
supernatant of the clone 2.4G2 for 15 minutes (4uC). Surface
antigens were stained for 15 minutes and cells were washed with
FACS buffer once.
For quantification of neutrophils in whole blood samples, the
following antibodies were used: anti-mouse CD45 eFluor450
(eBioscience), PE rat anti-mouse CD11b and Alexa Fluor 647 anti-
mouse Ly6G (BD Pharmingen). Coagulation of whole blood was
Figure 7. The induction of cardiac ruptures by HSA-Flag-TWEAK depends on neutrophils. Mice were treated with an anti-Ly6G antibody
to deplete neutrophils (A) in the myocardium as measured by immunohistological staining and (B) in the peripheral blood as measured by FACS
analysis. (C) Neutrophil depletion did not affect survival after MI in PBS and HSA-Flag-TWEAK treated mice. (D) The occurrence of cardiac ruptures was
significantly reduced after anti-Ly6G antibody treatment in the HSA-Flag-TWEAK treated group in comparison to the neutrophil intact control.
doi:10.1371/journal.pone.0078938.g007
TWEAK and Myocardial Infarction
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averted by heparinization. Following staining of surface antigens,
erythrocytes were lysed by incubation with fixation permeabiliza-
tion concentrate (eBioscience) in fixation permeabilization diluent
(eBioscience) for 45 minutes at room temperature.
Cells were analysed in FACS buffer on a BD FACSCanto II
flow cytometer (BD, Heidelberg, Germany). Data was analysed
with FlowJo (TreeStar Inc) software (version 7.6.5).
Neutrophil Depletion Study
Mice were injected i.p. with HSA-Flag-TWEAK (32 mg/mouse)
or placebo control (PBS) right after inducing myocardial infarction
and on days 3 and 6 after MI. Neutrophil granulocytes were
depleted in placebo and HSA-Flag-TWEAK-treated animals by
i.p. administration of 250 mg of an anti-Ly6G antibody (clone
1A8; Biolegend, London, United Kingdom) or istotype control
(clone RTK2758; Biolegend) one day before infarct surgery (day
21) and on days 5 and 7. On day 8 after MI, animals were
sacrificed, peripheral blood samples were taken for FACS analysis
of neutrophils, and sections of mouse myocardium were fixed in
4% paraformaldehyde overnight, embedded in paraffin, and
stained for neutrophils.
Statistical Analysis
All data are expressed as mean and standard error of mean.
Mortality data were compared using a log rank test. Statistical
analysis was performed using GraphPad Instat3 software (version
3.0; La Jolla, USA). Treatment groups were compared to the
placebo group using two-tailed unpaired student’s t test. Statistical
significance was achieved when two-tailed p,0.05.
Results
TWEAK and Fn14 are Upregulated after MI
We analyzed mRNA expression of TWEAK and its receptor
Fn14 in mouse heart samples 3 days and 56 days after MI.
TWEAK was significantly upregulated 3 days after MI compared
to sham operated animals (figure 1A). Fn14 was also significantly
upregulated 3 days and 56 days after MI (figure 1B). Immuno-
histological staining revealed increased expression of Fn14 in the
border zone 3 days after MI in comparison to sham operated mice
(figure 1C), which was mainly confined to cardiac fibroblasts
(figure 1D). These findings could be verified with isolated adult
mouse cardiomyocytes and fibroblasts (figure 1E, 1F) with only the
latter cells expressing Fn14. These results indicate that both
TWEAK and its receptor Fn14 are upregulated after MI in mice
and increased Fn14 expression is mainly confined to fibroblasts,
suggesting an involvement of the TWEAK-Fn14 axis in cardiac
wound healing.
Exogenous Soluble TWEAK Increases Mortality after MI
and is Associated with Cardiac Ruptures
Treatment of mice with HSA-Flag-TWEAK resulted in
significantly lower survival rates when compared to placebo
treated mice (figure 2A) without apparent changes in cardiac
diameters (table 1), relative body weight, or relative weights of
individual organs, namely heart, right ventricle, lung, and spleen
(data not shown). The increase in mortality was mainly due to left
ventricular ruptures (figure 2B); other reasons for death could not
be identified in HSA-Flag-TWEAK treated mice. Thus, exoge-
nous administration of HSA-Flag-TWEAK causes early death of
infarcted mice mainly due to cardiac ruptures.
Extracellular Matrix Remodelling and HSA-Flag-TWEAK
Treatment
Different infarct sizes could explain an increase in left
ventricular rupture. However, after 6 hours of MI, no differences
in infarct size, measured by Evans blue/TTC staining could be
found in HSA-Flag-TWEAK treated mice in comparison to
control mice (infarct size/area at risk, placebo vs. HSA-Flag-
TWEAK, 48.166% vs. 61.267%, p= n.s.). Moreover, changes in
the cardiac architecture after MI could be responsible for the
phenotype. Yet, echocardiography demonstrated that left ventric-
ular end-systolic (ESA) and end-diastolic area (EDA), as well as
fractional shorting (FS) were not significantly altered between the
groups (table 1).
Since extracellular matrix remodeling has a pivotal role for
healing after MI, we investigated components of extracellular
matrix remodeling 3 days after MI, i.e. before cardiac ruptures
occurred. Markers of extracellular matrix remodelling were not
compromised on mRNA levels in HSA-Flag-TWEAK animals: In
the infarcted area expressions of collagen1a1, collagen1a2, and
matrix metalloproteinases (MMPs) 2, 3, 8, and 9 were not
significantly altered (figure 3A, figure 3B). The activities of MMP-2
and MMP-9 as assessed by gelatine zymography were not different
between the two treatment groups (figure 3C). The mRNA
expressions of Tissue MMP inhibitors (TIMP) 2 and 3 were not
different 3 days after MI, neither were the expression levels of
vascular endothelial growth factor (VEGF) changed in HSA-Flag-
TWEAK treated mice (figure 3D). Thus, differences in extra-
celluar matrix remodeling, left ventricular architecture or infarct
size cannot explain our phenotype.
Role of HSA-Flag-TWEAK for Apoptosis after MI
We next tested the hypothesis that apoptosis of cardiomyocytes
may have contributed to the left ventricular rupture. Assessment of
LV by TUNEL staining and immunohistological staining for
cleaved PARP suggested that HSA-Flag-TWEAK treatment did
not alter the rate of apoptosis in either MI or sham-operated mice,
measured with TUNEL-staining (figure 4A) and immunohistolog-
ical staining for cleaved PARP (figure 4B).
Cytokine Array Screening and Bioinformatics Analysis
Detected an Accentuation of Inflammation by HSA-Flag-
TWEAK Treatment
Although HSA-Flag-TWEAK has a lower inflammatory activity
than membrane TWEAK or TNF, it nevertheless stimulates at low
levels the classical NFkB pathway and also strongly triggers the
alternative NFkB pathway which by cell type-specific mechanisms
can crosstalk into the classical NFkB pathway. We thus used
protein microarray technology to study alterations in the cytokine
expression in the infarcted area 3 days after MI with HSA-Flag-
TWEAK treatment. To better understand their functional
significance we mapped the protein microarray data bioinforma-
tically by ANOVA after normalization on the human interactome
(figure 5).
The protein levels for a number of potential mediators of an
exaggerated immune response were increased following in vivo
treatment with HSA-Flag-TWEAK: Interferon-c (IFN-c), inter-
leukin-12 (IL-12), glucocorticoid induced tumor necrosis factor
receptor family related gene (GITR), monocyte chemotactic
protein-1/-5 (MCP-1/-5), regulated and normal T cell expressed
and secreted (RANTES; CCL5) and IL-5 (table 2). Functional
clusters indicate interleukin and chemokine pathways and entities,
connected by the JAK/STAT pathway. In conclusion, the protein
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array data together with bioinformatical modeling suggested a role
of TWEAK stimulation in inflammatory cell activation.
Immune Cells are Involved in HSA-Flag-TWEAK Mediated
Effects
The microarray/bioinformatical results also indicated the
potential involvement of immune cells in the detrimental effects
of HSA-Flag-TWEAK. Therefore, we next analyzed the content
of different immune cell subsets in mice hearts after MI by FACS-
analysis. We found significantly more CD45+ cells infiltrating the
infarcted area of HSA-Flag-TWEAK in comparison to placebo
treated mice (figure 6A). Histological staining proved increased
infiltration of neutrophils into the border zone of mice treated with
HSA-Flag-TWEAK (figure 6B).
Several publications describe a correlation between the occur-
rence of cardiac ruptures and neutrophil infiltration [28,29]. To
test whether the HSA-Flag-TWEAK-mediated increase in neu-
trophil infiltration is responsible for cardiac ruptures, we depleted
neutrophils in mice in vivo by treating them with anti-Ly6G
antibodies after HSA-Flag-TWEAK application. Effective deple-
tion of neutrophils was confirmed in heart tissue slices (figure 7A)
and by flow cytometry in peripheral blood samples using
CD11b+Ly6G+ as a percent of CD45+ cells (figure 7B).
Treatment with HSA-Flag-TWEAK resulted in significantly
increased mortality in neutrophil intact mice (figure 7C). Neutro-
phil depletion in HSA-Flag-TWEAK challenged mice did not
modify MI-induced mortality (figure 7C), but significantly reduced
the occurrence of cardiac ruptures in comparison to the placebo
groups (figure 7D).
Whereas systemic neutrophil depletion did not prevent the
increased mortality of HSA-Flag-TWEAK treated mice after
chronic MI, the depletion of neutrophils significantly decreased
the occurrence of cardiac ruptures in HSA-Flag-TWEAK treated
mice.
Discussion
Inflammation is an important contributor to heart failure
[30,31]. The goal of this study was to find an immunomodulatory
therapy to improve cardiac repair and LV remodelling after MI.
We tested the effects of exogenous administration of HSA-Flag-
TWEAK, a recombinant variant of the naturally occurring soluble
form of the multi-functional cytokine TWEAK which, together
with its receptor Fn14, is robustly up-regulated after MI and can
influence cardiac repair [32], ischemic tolerance [12], inflamma-
tory processes, and apoptosis [9]. We hypothesized that this
TWEAK variant would beneficially influence wound healing after
MI; however, our experiments demonstrated that administration
of the variant in a model of non-reperfused infarction resulted in
high mortality and an increased incidence of rupture.
There are several potential mechanisms for this finding that
have to be taken into account:
Non-reperfused Infarction
We used a MI model with a non-reperfused infarction. It is
likely that, at least for several days and until neovessels are formed
the agent TWEAK may be only delivered to the border zone and
to the non-infarcted myocardium. Findings may have been
different in models of reperfused infarction.
Changes in Extracellular Matrix Remodelling
Extracellular matrix deposition and organization play a major
role in LV remodeling, and both collagen and collagen degrading
enzymes are important contributors to the development of cardiac
ruptures [33]. A loss of collagen struts which tether cardiomyo-
cytes to each other can cause lengthening of infarcted cardiomy-
ocytes under continuous stretch. This leads to infarct expansion
and can provoke cardiac ruptures [34]. Thus, one potential
mechanism for impaired healing and the occurrence of cardiac
ruptures in HSA-Flag-TWEAK treated mice could be an
imbalance of collagen content in the scar region, e.g. inadequate
collagen production in the scar area or perturbed expression of
collagen degrading enzymes or their inhibitors. We could show,
that fibroblasts, which are the main sources for collagen, highly
express Fn14 and can therefore respond to TWEAK. Neverthe-
less, we could not observe any effect of HSA-Flag-TWEAK on
either the expression of collagen, MMPs or TIMPs, nor on the
activity of MMPs in mice after MI.
Changes in Inflammation
Inflammation is another major player in myocardial ruptures.
We could recently show that CD4+ T cells are of importance in
wound healing after MI and deficiency in these cells leads to early
mortality with a high incidence of cardiac ruptures [30]. Other
immune cells like macrophages and neutrophils can also influence
wound healing after MI. Depleting monocytes and macrophages
with clodronate-containing liposomes increases mortality in mice
after MI due to thromboembolic events [35]. The depletion of
neutrophils in dogs [36] or treatment with inhibitors of neutrophil
adhesion in pigs [37] led to a significant decrease in infarct size
suggesting that neutrophils are involved in myocardial injury.
TWEAK exhibits pro-inflammatory properties while genetic
ablation of TWEAK or the application of TWEAK-blocking
antibodies reduces inflammation and disease severity in TNBS-
induced colitis [38]. We could show HSA-Flag-TWEAK to
upregulate a number of cytokines which share the common
feature of controlling trafficking and activation of innate immune
cells: IFN-c [39], MCP-1 [40] and RANTES [41]:
IFN-c can control trafficking, activation and apoptosis of
polymorphonuclear neutrophils (PMN) [39]. Furthermore, PMN
were shown to produce and to release IFN-c in response to IL-12
[42] and increased levels of this cytokine can lead to reduced
wound strength [43]. IFN-c can induce left ventricular dilation
and impaired systolic function as was shown with mice overex-
pressing this cytokine [44].
MCP-1 mediates the recruitment of monocytes, lymphocytes
[45], and neutrophils [40]. In patients, elevated MCP-1 levels are
associated with attenuated remodeling during the first few days
after MI. In the sub-acute phase of infarction, a rise in MCP-1 is
associated with progressive adverse ventricular remodeling [46].
HSA-Flag-TWEAK treatment also up-regulated tissue levels of
RANTES, which is produced by endothelial cells [47] and
lymphocytes [48] and acts as a potent chemoattractant for
monocytes [41], NK cells [49], and neutrophils [50] during
inflammation. Treatment with RANTES antagonists decreased
reperfusion injury in atherosclerotic mice [51]. This cytokine
interacts with CCR1, CCR3, and CCR5. CCR1-deficiency, but
not CCR5-deficiency affects the infarct size after MI in mice,
whereas the latter was shown to be important for LV remodelling
[52,53].
In good accordance with the high expression of the above
mentioned cytokines, we found significantly increased numbers of
infiltrating CD45+ immune cells within the infarcted area of hearts
from mice challenged with HSA-Flag-TWEAK. Among these
cells, especially neutrophils were increased, indicating that
TWEAK promotes the recruitment or trafficking of these cells to
sites of inflammation. A good correlation between neutrophil
infiltration and the occurrence of cardiac ruptures was demon-
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strated in patients after MI [28]. Haile et al. showed TWEAK to
induces the passage of neutrophils to the abluminal side in an
in vitro model of the blood-brain barrier [54] and TNF was also
shown to control the recruitment of neutrophils in immune
complex peritonitis [55] and during airway inflammation [56].
Therefore, our data imply that the TWEAK-induced recruitment
of neutrophils to the infarcted myocardium might be mediated by
NFkB dependent production of IFN-c, MCP-1 and RANTES.
Functional Involvement of Neutrophils in Cardiac
Ruptures
To functionally test whether neutrophils are the underlying
cause of HSA-Flag-TWEAK-induced cardiac ruptures, we
depleted neutrophils prior to MI. This significantly reduced the
incidence of ruptures without affecting HSA-Flag-TWEAK-
induced global mortality. Since the mortality in mice treated with
HSA-Flag-TWEAK was not affected by neutrophil depletion
despite a marked reduction in the incidence of cardiac ruptures,
we propose that additional mechanisms must be involved in
TWEAK-induced mortality. Besides the cytokines MCP-1/-5 and
RANTES, IFN-c, IL-12 and IL-5 were highly upregulated 3 days
after MI in HSA-Flag-TWEAK treated mice. The elevated levels
of these cytokines suggest an involvement of other immune cells in
HSA-Flag-TWEAK induced mortality after MI.
In summary, we demonstrate that treatment of mice with
recombinant HSA-Flag-TWEAK after MI results in cardiac
ruptures in a neutrophil-dependent manner. These results
demonstrate the interplay between TWEAK, leukocytes, and
cardiac wound healing after MI.
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